Medtronic PLC $MDT Holdings Boosted by Ieq Capital LLC

Ieq Capital LLC grew its stake in Medtronic PLC (NYSE:MDT – Free Report) by 201.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 304,001 shares of the medical technology company’s stock after acquiring an additional 203,045 shares during the period. Ieq Capital LLC’s holdings in Medtronic were worth $26,232,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MDT. Focus Advisor Solutions LLC increased its position in Medtronic by 310.2% during the third quarter. Focus Advisor Solutions LLC now owns 64,112 shares of the medical technology company’s stock worth $5,532,000 after buying an additional 48,483 shares during the last quarter. Checchi Capital Advisers LLC lifted its position in shares of Medtronic by 32.4% in the third quarter. Checchi Capital Advisers LLC now owns 5,418 shares of the medical technology company’s stock valued at $468,000 after buying an additional 1,327 shares during the last quarter. Boston Partners boosted its stake in shares of Medtronic by 22.9% during the 3rd quarter. Boston Partners now owns 4,672,722 shares of the medical technology company’s stock worth $403,236,000 after acquiring an additional 870,606 shares during the period. Independent Advisor Alliance boosted its stake in shares of Medtronic by 11.7% during the 3rd quarter. Independent Advisor Alliance now owns 78,275 shares of the medical technology company’s stock worth $7,039,000 after acquiring an additional 8,203 shares during the period. Finally, OneAscent Financial Services LLC acquired a new position in shares of Medtronic during the 3rd quarter worth approximately $301,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on MDT shares. Stifel Nicolaus increased their price target on Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a research note on Wednesday, September 2nd. BTIG Research lifted their price objective on shares of Medtronic from $99.00 to $109.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 19th. Wells Fargo & Company increased their price objective on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research report on Wednesday, September 2nd. Finally, Mizuho set a $115.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $104.17.

Read Our Latest Analysis on Medtronic

Insiders Place Their Bets

In other news, CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares of the company’s stock, valued at $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is currently owned by insiders.

Trending Headlines about Medtronic

Here are a few of the latest headlines about MDT:

  • Positive Sentiment: Analyst coverage points to growth potential from adoption of Medtronic’s Hugo surgical robot, international expansion and Neuroscience products. A separate report projects strong growth in connected health devices through 2032, a market that includes Medtronic. Medtronic growth prospects Connected health devices market report
  • Neutral Sentiment: A preview of Medtronic’s fiscal second-quarter results focused on expected metrics but did not report actual results, leaving investors awaiting the earnings update. Medtronic Q2 earnings preview
  • Negative Sentiment: The outlook discussion also flags margin and currency headwinds, which could limit the benefit of growth in Hugo, international markets and Neuroscience. Medtronic hold analysis

Medtronic Stock Performance

NYSE:MDT opened at $100.57 on Friday. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $128.64 billion, a PE ratio of 24.77, a price-to-earnings-growth ratio of 2.36 and a beta of 0.56. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The stock’s 50-day simple moving average is $94.44 and its 200 day simple moving average is $88.47.

Medtronic (NYSE:MDT – Get Free Report) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

About Medtronic

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Stories

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.